OVER THE LAST YEAR, companies like GlaxoSmithKline, Bristol-Myers Squibb, Och-Ziff, and AB InBev joined an illustrious list that includes Siemens, Kellogg Brown Root, Technip, and Eni.
What do they all have in common?
Each has now paid significant fines – and in at least one case, seen jail time for their CEO – related to violations of the U.S. Foreign Corrupt Practices Act that involve joint ventures in emerging markets.
Anti-Bribery and Corruption: Partner Screening and Due Diligence in Emerging Market JVs
By
Joshua Kwicinski | Tuesday, October 25, 2016
POSTS BY TOPIC
- Joint Venture Dealmaking (40)
- Joint Venture Governance (38)
- Joint Venture Management (28)
- Joint Venture Strategy (17)
- Joint Venture Boards and Directors (12)
- Oil & Gas (10)
- News Analysis (7)
- Healthcare (5)
- Best Practice (4)
- Joint Venture Talent Engagement (3)
- Strategic Alliances (3)
- Aerospace and Defense (2)
- Cross-Border Joint Ventures (2)
- Joint Venture Shareholders (2)
- Technology Partnerships (2)
- Chemicals (1)
- Conflicts of Interest (1)
- Emerging Markets (1)
- Human Resources (1)
- Insurance (1)
- Joint Venture CEOs and Management Teams (1)
- Joint Venture Operating Models (1)
- Joint Venture Partner Selection (1)
- Joint Ventures in Private Equity (1)
- Metals & Mining (1)